SCHEMBL3015946

SCHEMBL3015946

O=S(=O)(c1cc(Cl)cc(Cl)c1)C1CCN(c2nc(Cc3ccccc3)cs2)CC1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 3/20 0.44
KCNH2 Q12809 2/20 0.40
HTR2C P28335 1/20 0.40
HRH4 Q9H3N8 2/20 0.38
SPR P35270 1/20 0.38
DNM1L O00429 3/20 0.37
MEN1 O00255 1/20 0.37
LMNA P02545 1/20 0.37
MAPK1 P28482 1/20 0.37
KMT2A Q03164 1/20 0.37
RAB9A P51151 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MAPT P10636 2/20 0.36
NPC1 O15118 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
CNR1 P21554 1/20 0.36
GBA1 P04062 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3013512 0.93 HTR2A (0.44) HTR2AKCNH2HTR2CHRH4SPR
SCHEMBL3016582 0.93 MAPT (0.40) HTR2AKCNH2HTR2CLMNAMAPK1
SCHEMBL3014724 0.92 HTR2A (0.46) HTR2AKCNH2HTR2CMEN1LMNA
SCHEMBL3021485 0.91 MAPT (0.35) HTR2AKCNH2HTR2CSPRDNM1L
SCHEMBL3005427 0.90 RAB9A (0.37) HTR2AKCNH2HTR2CSPRDNM1L
SCHEMBL3003648 0.90 SMN1; SMN2 (0.38) DNM1LLMNAKMT2ARAB9ASMN1; SMN2
SCHEMBL3006962 0.90 SMN1; SMN2 (0.35) HTR2ADNM1LMEN1LMNAMAPK1
SCHEMBL3020188 0.89 DNM1L (0.37) HTR2ADNM1LRAB9ASMN1; SMN2MAPT
SCHEMBL3015155 0.89 HTR2A (0.41) HTR2AKCNH2HTR2CHRH4SPR
SCHEMBL3013788 0.88 HTR2A (0.39) HTR2AKCNH2HTR2CHRH4SPR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA HTR2A 752/4885KCNH2 3130/4885HTR2C 1153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.